Remission rates according to the International Working Group response criteria
. | . | . | . | . | . | IWG response . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | IPSS (%) . | . | . | . | % hematologic response . | . | . | . | . | |||||
| Treatment . | No. patients . | Low . | Int1 . | Int2 . | High . | Overall . | CR . | PR . | Median survival, mo . | % HI-major . | |||||
| Azacitidine17 | 99 | 5* | 53 | 23 | 17 | 11 | 10 | 1 | 20 | 36 (+minor) | |||||
| Decitabine18 | 89 | 31 | 43 | 26 | 17 | 9 | 8 | 22.3/13.3† | 13 | ||||||
| Tipifarnib19 | 82 | 17 | 39 | 44 | 12 | 7 | 5 | 11.9‡ | 22 | ||||||
| Arsenic20 | 101 | NA | 39§ | NA | 61∥ | 1 | 1 | 0 | NA | 20 | |||||
. | . | . | . | . | . | IWG response . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | IPSS (%) . | . | . | . | % hematologic response . | . | . | . | . | |||||
| Treatment . | No. patients . | Low . | Int1 . | Int2 . | High . | Overall . | CR . | PR . | Median survival, mo . | % HI-major . | |||||
| Azacitidine17 | 99 | 5* | 53 | 23 | 17 | 11 | 10 | 1 | 20 | 36 (+minor) | |||||
| Decitabine18 | 89 | 31 | 43 | 26 | 17 | 9 | 8 | 22.3/13.3† | 13 | ||||||
| Tipifarnib19 | 82 | 17 | 39 | 44 | 12 | 7 | 5 | 11.9‡ | 22 | ||||||
| Arsenic20 | 101 | NA | 39§ | NA | 61∥ | 1 | 1 | 0 | NA | 20 | |||||
IWG indicates International Working Group; IPSS, International Prognostic Scoring System; CR, complete remission; PR, partial remission; HI, hematologic improvement; Int1, IPSS intermediate-1; Int2, IPSS intermediate-2; TTL, time to leukemia; NA, not available.
Evaluated in only 39 of 99 patients.
Data are for responders and nonresponders, respectively.
Time to leukemia or death: 6.4 months.
Data for combined Low and Int1.
Data combined for Int2 and High.